secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001193125-26-178806
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.02, 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics Q1 net loss $18.9M, CFO retiring, CAMP4 license terminated, pociredir trial planned H2 2026
--------------------------------------------------------------------------------

- CFO Alan Musso retiring; will stay until successor named then consultant through Feb 2027.
- Terminated CAMP4 license for Diamond-Blackfan anemia program; no further milestone/royalty payments.
- Q1 net loss $18.9M ($17.7M Q1 2025); cash $333.3M, runway into 2029.
- Positive pociredir Phase 1b data: HbF induction, hemolysis/anemia improvements; registration-enabling trial H2 2026.
- Board appointed Josh Lehrer M.D., independent, receives option for 64,000 shares at $8.08.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/0001193125-26-178806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/fulc-20260423.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-178806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer